Recently, in vitro diagnostic (IVD) antibodies has been widely used as tools for disease diagnosis, prognosis, and therapeutic monitoring. As a leading company in the IVD field, Creative Biolabs has successfully established an advanced technology platform for discovering high-quality IVD antibodies and developing IVD kits. Here, we are happy to introduce our high-quality IVD antibody development service against bladder cancer antigen-4 (BLCA-4) marker for the diagnosis of bladder cancer.
BLCA-4 is one of the six nuclear matrix proteins (NMPs) firstly identified in 1996 with changes in nuclear structure and can affect gene expression. Studies have shown that BLCA-4 is expressed exclusively in bladder cancer cells, but not in normal tissues, which indicates that BLCA-4 may play an important role in the carcinogenesis process. What’s more, it has been reported that BLCA-4 upregulated of genes related to enhance tumorigenesis and tumor invasiveness, including the cyclins, interleukin-8 (IL8), thrombomodulin (TM), and interleukin-1alpha (IL-1α). BLCA-4 over-expression results in increased TM expression, which sustains the microcirculation needed for tumor cell survival.
Fig.1 BLCA-4 expression in the bladder cancer tissue (a), the adjacent normal tissue (b), and the normal tissue (c).1
BLCA-4 can be only found in the early stage of bladder cancer, but not in normal tissues, which indicates that BLCA-4 may be a sensitive and specific urinary marker of bladder cancer. Also, the absence of high BLCA-4 levels in patients with various benign urologic disorders, such as urinary tract infection, catheterization, or cystitis will further strengthen the potential of this factor. Clinical studies have suggested that BLCA-4 was significantly higher in the bladder cancer group with no relation to age, gender, growth pattern, grade or stage of the disease. In this condition, BLCA-4 can be used as specific bladder cancer urinary marker to identify individuals in the early stages of bladder cancer, thus, affecting the therapeutic approach and prognosis of patients.
Recently, antibody-based in vitro diagnostics have been extensively used in many fields, such as disease screening and therapeutic monitoring. Immunotechnologies such as immunonephelometry and sandwich ELISA have greatly accelerated the development of IVD technology. As a pioneer company in this area, Creative Biolabs is able to offer a series of IVD antibody development services to meet every client’s requirements. With our versatile IVD platform, Creative Biolabs is proud to develop novel BLCA-4-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates).
Creative Biolabs is dedicated to accelerating your program a success. In addition to BLCA-4 marker, we also focus on other potential markers of bladder cancer to improve diagnostic accuracy. If you are interested in our IVD antibodies discovery services, please contact us for more details.
Reference
For Research Use Only.
